Cargando…
Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study
INTRODUCTION: There is currently no validated score capable of classifying cancer-associated pulmonary embolism (PE) in its full spectrum of severity. This study has validated the EPIPHANY Index, a new tool to predict serious complications in cancer patients with suspected or unsuspected PE. METHOD:...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168567/ https://www.ncbi.nlm.nih.gov/pubmed/37159465 http://dx.doi.org/10.1371/journal.pone.0266305 |
_version_ | 1785038880425115648 |
---|---|
author | Sánchez-Cánovas, Manuel Jimenez-Fonseca, Paula Fernández Garay, David Cejuela Solís, Mónica Casado Elía, Diego Coma Salvans, Eva de la Haba Vacas, Irma Gómez Sánchez, David Fernández Montés, Ana Morales Giménez, Roberto Biosca Gómez de Tejada, Mercedes Arrazubi Arrula, Virginia Sequero López, Silvia Otero Candelera, Remedios Sánchez Cendra, Cristina Justo de la Peña, Marina Moreno Muñoz, Diana Orillo Sarmiento, Mayra Martínez de Castro, Eva García Escobar, Ignacio Bernal Vidal, Alejandro Ortega Moran, Laura Muñoz Martín, Andrés J. Sánchez Bayona, Rodrigo Martínez Ortiz, María José Ayala de la Peña, Francisco Vicente, Vicente Carmona-Bayonas, Alberto |
author_facet | Sánchez-Cánovas, Manuel Jimenez-Fonseca, Paula Fernández Garay, David Cejuela Solís, Mónica Casado Elía, Diego Coma Salvans, Eva de la Haba Vacas, Irma Gómez Sánchez, David Fernández Montés, Ana Morales Giménez, Roberto Biosca Gómez de Tejada, Mercedes Arrazubi Arrula, Virginia Sequero López, Silvia Otero Candelera, Remedios Sánchez Cendra, Cristina Justo de la Peña, Marina Moreno Muñoz, Diana Orillo Sarmiento, Mayra Martínez de Castro, Eva García Escobar, Ignacio Bernal Vidal, Alejandro Ortega Moran, Laura Muñoz Martín, Andrés J. Sánchez Bayona, Rodrigo Martínez Ortiz, María José Ayala de la Peña, Francisco Vicente, Vicente Carmona-Bayonas, Alberto |
author_sort | Sánchez-Cánovas, Manuel |
collection | PubMed |
description | INTRODUCTION: There is currently no validated score capable of classifying cancer-associated pulmonary embolism (PE) in its full spectrum of severity. This study has validated the EPIPHANY Index, a new tool to predict serious complications in cancer patients with suspected or unsuspected PE. METHOD: The PERSEO Study prospectively recruited individuals with PE and active cancer or receiving antineoplastic therapy from 22 Spanish hospitals. The estimation of the relative frequency θ of complications based on the EPIPHANY Index categories was made using the Bayesian alternative for the binomial test. RESULTS: A total of 900 patients, who were diagnosed with PE between October 2017 and January 2020, were enrolled. The rate of serious complications at 15 days was 11.8%, 95% highest density interval [HDI], 9.8–14.1%. Of the EPIPHANY low-risk patients, 2.4% (95% HDI, 0.8–4.6%) had serious complications, as did 5.5% (95% HDI, 2.9–8.7%) of the moderate-risk participants and 21.0% (95% HDI, 17.0–24.0%) of those with high-risk episodes. The EPIPHANY Index was associated with overall survival (OS) in patients with different risk levels: median OS was 16.5, 14.4, and 4.4 months for those at low, intermediate, and high risk, respectively. Both the EPIPHANY Index and the Hestia criteria exhibited greater negative predictive value and a lower negative likelihood ratio than the remaining models. The incidence of bleeding at 6 months was 6.2% (95% HDI, 2.9–9.5%) in low/moderate-risk vs 12.7% (95% HDI, 10.1–15.4%) in high-risk (p-value = 0.037) episodes. Of the outpatients, serious complications at 15 days were recorded in 2.1% (95% HDI, 0.7–4.0%) of the cases with EPIPHANY low/intermediate-risk vs 5.3% (95% HDI, 1.7–11.8%) in high-risk cases. CONCLUSION: We have validated the EPIPHANY Index in patients with incidental or symptomatic cancer-related PE. This model can contribute to standardize decision-making in a scenario lacking quality evidence. |
format | Online Article Text |
id | pubmed-10168567 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-101685672023-05-10 Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study Sánchez-Cánovas, Manuel Jimenez-Fonseca, Paula Fernández Garay, David Cejuela Solís, Mónica Casado Elía, Diego Coma Salvans, Eva de la Haba Vacas, Irma Gómez Sánchez, David Fernández Montés, Ana Morales Giménez, Roberto Biosca Gómez de Tejada, Mercedes Arrazubi Arrula, Virginia Sequero López, Silvia Otero Candelera, Remedios Sánchez Cendra, Cristina Justo de la Peña, Marina Moreno Muñoz, Diana Orillo Sarmiento, Mayra Martínez de Castro, Eva García Escobar, Ignacio Bernal Vidal, Alejandro Ortega Moran, Laura Muñoz Martín, Andrés J. Sánchez Bayona, Rodrigo Martínez Ortiz, María José Ayala de la Peña, Francisco Vicente, Vicente Carmona-Bayonas, Alberto PLoS One Research Article INTRODUCTION: There is currently no validated score capable of classifying cancer-associated pulmonary embolism (PE) in its full spectrum of severity. This study has validated the EPIPHANY Index, a new tool to predict serious complications in cancer patients with suspected or unsuspected PE. METHOD: The PERSEO Study prospectively recruited individuals with PE and active cancer or receiving antineoplastic therapy from 22 Spanish hospitals. The estimation of the relative frequency θ of complications based on the EPIPHANY Index categories was made using the Bayesian alternative for the binomial test. RESULTS: A total of 900 patients, who were diagnosed with PE between October 2017 and January 2020, were enrolled. The rate of serious complications at 15 days was 11.8%, 95% highest density interval [HDI], 9.8–14.1%. Of the EPIPHANY low-risk patients, 2.4% (95% HDI, 0.8–4.6%) had serious complications, as did 5.5% (95% HDI, 2.9–8.7%) of the moderate-risk participants and 21.0% (95% HDI, 17.0–24.0%) of those with high-risk episodes. The EPIPHANY Index was associated with overall survival (OS) in patients with different risk levels: median OS was 16.5, 14.4, and 4.4 months for those at low, intermediate, and high risk, respectively. Both the EPIPHANY Index and the Hestia criteria exhibited greater negative predictive value and a lower negative likelihood ratio than the remaining models. The incidence of bleeding at 6 months was 6.2% (95% HDI, 2.9–9.5%) in low/moderate-risk vs 12.7% (95% HDI, 10.1–15.4%) in high-risk (p-value = 0.037) episodes. Of the outpatients, serious complications at 15 days were recorded in 2.1% (95% HDI, 0.7–4.0%) of the cases with EPIPHANY low/intermediate-risk vs 5.3% (95% HDI, 1.7–11.8%) in high-risk cases. CONCLUSION: We have validated the EPIPHANY Index in patients with incidental or symptomatic cancer-related PE. This model can contribute to standardize decision-making in a scenario lacking quality evidence. Public Library of Science 2023-05-09 /pmc/articles/PMC10168567/ /pubmed/37159465 http://dx.doi.org/10.1371/journal.pone.0266305 Text en © 2023 Sánchez-Cánovas et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Sánchez-Cánovas, Manuel Jimenez-Fonseca, Paula Fernández Garay, David Cejuela Solís, Mónica Casado Elía, Diego Coma Salvans, Eva de la Haba Vacas, Irma Gómez Sánchez, David Fernández Montés, Ana Morales Giménez, Roberto Biosca Gómez de Tejada, Mercedes Arrazubi Arrula, Virginia Sequero López, Silvia Otero Candelera, Remedios Sánchez Cendra, Cristina Justo de la Peña, Marina Moreno Muñoz, Diana Orillo Sarmiento, Mayra Martínez de Castro, Eva García Escobar, Ignacio Bernal Vidal, Alejandro Ortega Moran, Laura Muñoz Martín, Andrés J. Sánchez Bayona, Rodrigo Martínez Ortiz, María José Ayala de la Peña, Francisco Vicente, Vicente Carmona-Bayonas, Alberto Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study |
title | Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study |
title_full | Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study |
title_fullStr | Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study |
title_full_unstemmed | Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study |
title_short | Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study |
title_sort | prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: validation of the epiphany index in a prospective cohort of patients from the perseo study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168567/ https://www.ncbi.nlm.nih.gov/pubmed/37159465 http://dx.doi.org/10.1371/journal.pone.0266305 |
work_keys_str_mv | AT sanchezcanovasmanuel predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT jimenezfonsecapaula predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT fernandezgaraydavid predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT cejuelasolismonica predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT casadoeliadiego predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT comasalvanseva predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT delahabavacasirma predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT gomezsanchezdavid predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT fernandezmontesana predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT moralesgimenezroberto predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT bioscagomezdetejadamercedes predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT arrazubiarrulavirginia predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT sequerolopezsilvia predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT oterocandeleraremedios predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT sanchezcendracristina predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT justodelapenamarina predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT morenomunozdiana predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT orillosarmientomayra predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT martinezdecastroeva predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT garciaescobarignacio predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT bernalvidalalejandro predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT ortegamoranlaura predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT munozmartinandresj predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT sanchezbayonarodrigo predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT martinezortizmariajose predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT ayaladelapenafrancisco predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT vicentevicente predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy AT carmonabayonasalberto predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy |